ClinicalTrials.gg
RecruitingNCT06956300Updated Feb 20, 2026

TMS for Cognitive Decline in Aging and Preclinical AD

An interventional study of Active rTMS and Sham rTMS in Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease and Healthy Aging, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 40 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Cognitive Dysfunction by Massachusetts General Hospital — 14 open to participants now, 16 under way, none of them phase 3. Cognitive Dysfunction · Massachusetts General Hospital.

Planned enrollment
8th of 27
80 · median 40
Started
2025
with 3 others
No phase
17 of 33
7 open now
Primary completion
2029-08
later than 15 of 15 live
Registered
28th of 33
by date

Among the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, this one is the 8th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2025, is one of 17 with no phase, reaches primary completion later than 15 of the 15 other live ones, and was the 28th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

14 of the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 40 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, or all of them as a file.
02

Study summary

In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical Alzheimer's disease.

This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls cognition. Changes resulting from this stimulation will be measured with behavioral tests, as well as by taking brain images with Magnetic Resonance Imaging (MRI).

Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.

03

Conditions studied

  • Prodromal Alzheimer's Disease
  • Preclinical Alzheimer's Disease
  • Healthy Aging
  • Cognitive Decline

Keywords

  • Transcranial Magnetic Stimulation
04

Who can participate

Ages eligible
40 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between the ages of 40-99
  2. Native English speakers
  3. Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points
  4. Cognitively normal older adults and individuals with preclinical Alzheimer's disease will be included.

Exclusion criteria

Exclusion Criteria:

  1. History of head trauma involving loss of consciousness or alteration in consciousness
  2. Another major neurologic or psychiatric condition
  3. Known presence of a structural brain lesion (e.g. tumor, cortical infarct)
  4. Any to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body
  5. Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
  6. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.
  7. Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging
  8. History of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.).
  9. Subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder.
  10. Subjects currently taking, or plan to take, medications which are highly epileptogenic. These include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Active TMS

    All participants will receive the same study interventions in a within-subject crossover design.

    Device: Active rTMS

  • Sham comparator
    Sham TMS

    All participants will receive the same study interventions in a within-subject crossover design.

    Device: Sham rTMS

Interventions

  • DeviceActive rTMS

    All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).

  • DeviceSham rTMS

    All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).

06

What researchers measure

Primary outcomes

  1. Changes in motivation

    This will be measured by ratings of grit on a 5-point scale using the Grit Scale (Duckworth, et al., 2007).

    Time frame: Baseline and post-treatment Day 11

  2. Changes in Brain Network Connectivity

    This will include changes in resting-state functional connectivity measured with functional Magnetic Resonance Imaging (fMRI)

    Time frame: Baseline and post-treatment Day 11

  3. Changes in Memory

    This will be measured with an associative memory task

    Time frame: Baseline and Post-Treatment Day 11

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Aug 2029, 52 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 52 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
May 4, 2025
StartActual
Apr 7, 2025
Primary completionEst.
Aug 31, 2029
CompletionEst.
Aug 31, 2029
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06956300
Responsible party
Alexandra Touroutoglou (Assistant Professor of Neurology, Harvard Medical School (HMS and HSDM)) — Principal investigator
First posted
May 4, 2025
Start date
Apr 7, 2025
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Feb 20, 2026

Study contacts

Alexandra Touroutoglou, PhD
Contact
atouroutoglou@mgh.harvard.edu
6176436348
Jordan Walter, BA
Contact
jwalter2@mgh.harvard.edu
6177266207

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion